Puma Biotechnology Inc

The asset exhibits a classic blow-off top with a long upper wick and high-volume exhaustion in Stage 2, suggesting medium-term reversal risk; short-term rejection at resistance and overbought conditions favor immediate bearish engagement through a sell now posture, targeting the recent resistance zone with rejection-based execution.

• ↑Q2 total revenue $56.5M (up from $49.2M YoY); NERLYNX product sales +27% QoQ.
• ↑2026 revenue guidance raised to $205–209M, reflecting strong market demand.
• ↓NERLYNX drives majority of sales, posing single‐product concentration risk.